EUAA

Redefining what the
#1 liquid biopsy can do.¹

Covers 740+ genes
and is the first to
unlock epigenomics^2,3

Important note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.

Product availability may vary depending on region.

Powered by Guardant Infinity™

Highest sensitivity
with a reportable range
down to 0.001% MAF²

Broad coverage
with >92% of patients
paying $0^†

MAF, mutant allele fraction.
*Median turnaround time from sample receipt to results.
†More than 92% of patients are assigned $0 by their insurance for a Guardant360 test.

Next >

Home Oncology Portfolio Partnerships European Policy

Fast results
in 7 days²*